Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
| 07-2019 | 04-2019 | 01-2019 | 10-2018 | 07-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 206 | 938 | 306 | 871 | 366 |
| Receivables | 290 | 158 | 246 | 241 | 315 |
| TOTAL | $687 | $1,316 | $883 | $1,434 | $773 |
| Non-Current Assets | |||||
| PPE Net | 253 | 283 | 312 | 346 | 374 |
| TOTAL | $253 | $283 | $312 | $346 | $374 |
| Total Assets | $940 | $1,599 | $1,195 | $1,780 | $1,147 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,040 | 2,801 | 2,378 | 2,968 | 1,992 |
| Accrued Expenses | 1,057 | 667 | 446 | 433 | 644 |
| TOTAL | $4,221 | $3,519 | $2,881 | $3,431 | $2,674 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 124 | 51 | 57 | 30 | 38 |
| TOTAL | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4,221 | $3,519 | $2,881 | $3,431 | $2,674 |
| Shareholders' Equity | |||||
| Common Shares | 129,532 | 129,188 | 127,940 | 126,505 | 125,565 |
| Retained earnings | -171,531 | -169,363 | -167,292 | -165,384 | -164,005 |
| Other shareholders' equity | 15,403 | 15,076 | 14,487 | 14,157 | 14,045 |
| TOTAL | $-3,281 | $-1,920 | $-1,686 | $-1,651 | $-1,527 |
| Total Liabilities And Equity | $940 | $1,599 | $1,195 | $1,780 | $1,147 |